Inflammatory bowel disease (IBD) is a chronic inflammatory disorder characterized by damage to the intestinal mucosa, which is caused by a combination of factors. These include genetic and epigenetic alterations, environmental influence, microorganism interactions, and immune conditions. Some populations with IBD show a cancer-prone phenotype. Recent studies have provided insight into the involvement of RNA modifications in the specific pathogenesis of IBD through regulation of RNA biology in epithelial and immune cells. Studies of several RNA modification-targeting reagents have shown preferable outcomes in patients with colitis. Here, we note a new awareness of RNA modification in the targeting of IBD and related diseases, which will contribute to early diagnosis, disease monitoring, and possible control by innovative therapeutic approaches.
RNA Modification in Inflammatory Bowel Diseases / Nakayama, Mika; Ozato, Yuki; Tsuji, Yoshiko; Arao, Yasuko; Otsuka, Chihiro; Hamano, Yumiko; Sumi, Genzo; Ofusa, Ken; Uchida, Shizuka; Vecchione, Andrea; Ishii, Hideshi. - In: BIOMEDICINES. - ISSN 2227-9059. - 10:7(2022), pp. 1-15. [10.3390/biomedicines10071695]
RNA Modification in Inflammatory Bowel Diseases
Vecchione, Andrea;
2022
Abstract
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder characterized by damage to the intestinal mucosa, which is caused by a combination of factors. These include genetic and epigenetic alterations, environmental influence, microorganism interactions, and immune conditions. Some populations with IBD show a cancer-prone phenotype. Recent studies have provided insight into the involvement of RNA modifications in the specific pathogenesis of IBD through regulation of RNA biology in epithelial and immune cells. Studies of several RNA modification-targeting reagents have shown preferable outcomes in patients with colitis. Here, we note a new awareness of RNA modification in the targeting of IBD and related diseases, which will contribute to early diagnosis, disease monitoring, and possible control by innovative therapeutic approaches.File | Dimensione | Formato | |
---|---|---|---|
Nakayama_RNA-Modification_2022.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
2.37 MB
Formato
Adobe PDF
|
2.37 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.